The legal scrutiny follows a disastrous August 10, 2026, disclosure concerning the company’s PreciSION CF Phase 2a trial. Sionna revealed that its experimental drug SION-719 failed to meet its primary activity endpoint—a reduction in sweat chloride levels—when administered alongside the standard cystic fibrosis treatment Trikafta. Following the announcement, the company’s share price collapsed by $46.54, closing at just $4.50.
In section Releases
Pomerantz LLP Launches Investigation Into Sionna Therapeutics
Sionna Therapeutics faces a potential class action investigation after the company’s stock plummeted more than 91% in a single day. The inquiry, led by Pomerantz LLP, centers on whether executives misled shareholders regarding the clinical efficacy of its lead nucleotide binding domain stabilizer programs.
Pomerantz LLP is now reviewing whether Sionna and its leadership engaged in securities fraud or unlawful business practices leading up to the trial results. Investors impacted by the decline are being directed to contact Danielle Peyton at the firm to discuss potential litigation. The investigation joins a long history of securities work for the New York-based firm, which specializes in corporate misconduct and breach of fiduciary duty claims.
Comments (0)
No comments yet. Be the first!